Endovasc Study Published in Heart Watch Periodical; Abstract Titled, ''Nicotine May Trigger Stem Cells to Differentiate into Viable Cardiac Cells''.

Business Editors/Health/Medical Writers

MONTGOMERY, Texas--(BUSINESS WIRE)--April 15, 2004

Endovasc Inc. (OTCBB: EVSC), announced today that collaborative research directed by Dr. Yong-Jian Geng at Texas Heart Institute's Heart Failure and Stem Cell Research Laboratory has been published in the Spring 2004 addition of Heart Watch, www.endovasc.com/investor/endonews.php. The recently completed study explored the growing theory suggesting that nicotine, given at low doses may be useful in treating heart failure. Endovasc is pleased to report that the outcome of these studies confirm and extend earlier studies supporting the case that nicotine can boost the regenerative abilities of stem cells in patients with heart failure.

Heart Watch is a quarterly newsletter published by the Texas Heart Institute in cooperation with St. Luke's Episcopal Hospital and targeted toward cardiologists and cardiovascular surgeons. Its aim is to keep physicians abreast of important work being done here and elsewhere to reduce the devastating toll of cardiovascular disease through research, education, and patient care. The Spring 2004 addition of Heart Watch will be available in few days at www.texasheart.org/hwatch.html.

Since spring 2003, researchers in THI's Heart Failure and Stem Cell Research Laboratory have been studying the effects of a purified form of nicotine on stem cell growth and differentiation. These findings complement other stem cell therapy research underway at THI. Dr. Geng and his team, along with James T. Willerson, MD, medical director and director of Cardiology Research, have found evidence that cardiac stem cells transplanted from one species of animal into another can develop into new cardiovascular tissue.

In other news important news, UT Health Science Center recently received a $25 million donation for stem cell research from an anonymous donor.

http://publicaffairs.uth.tmc.edu/Media/newsreleases/nr2004/ 25million_stemcell.html

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field.)

Angiogenix, one of Endovasc's lead drug candidates, is derived from the tobacco plant; commonly known as nicotine, it is the active form of the (-) s-isomer. Recently, researchers have begun to look at the potentially beneficial effects of purified nicotine in an alternative formulation and at doses far below that ingested by smoking. Both angiogenesis and stem cells have been the focus of intense interest by the medical community since both processes hold the potential to be exploited to therapeutic advantage. The Company believes that Angiogenix could effectively stimulate stem cells for therapeutic regeneration for a variety of medical therapies. Millions of patients worldwide suffer from chronic myocardial ischemia, ischemic bowel, ischemic neurovascular disease, and other manifestations of atherosclerosis, all of whom could potentially benefit from Angiogenix if it proves to be commercially viable.

About Texas Heart Institute

World-renowned cardiovascular surgeon Denton A. Cooley, M.D., founded the Texas Heart Institute in 1962 for the study and treatment of diseases of the heart and blood vessels. Together with the Institute's clinical partner, St. Luke's Episcopal Hospital, it has been ranked among the nation's top 10 heart centers in an annual survey published by U.S. News & World Report for the past 13 years.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release.